vimarsana.com

Latest Breaking News On - Chardan capital - Page 6 : vimarsana.com

Chardan Capital Cuts Freightos (NASDAQ:CRGO) Price Target to $6.00

Freightos (NASDAQ:CRGO – Free Report) had its target price decreased by Chardan Capital from $8.00 to $6.00 in a report released on Thursday morning, Benzinga reports. Chardan Capital currently has a buy rating on the stock. Freightos Price Performance Shares of NASDAQ:CRGO opened at $2.35 on Thursday. Freightos has a twelve month low of $1.85 […]

Alphacore-capital
Investment-office
Mg-plc
Nasdaq
Webcargo-airline-control-panel
Freightos-company-profile
Capital-management
Free-report
Chardan-capital
Get-free-report
Core-capital

Insider Selling: Solid Power, Inc. (NASDAQ:SLDP) CTO Sells $315,000.00 in Stock

Solid Power, Inc. (NASDAQ:SLDP – Get Free Report) CTO Joshua Buettner-Garrett sold 187,500 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $1.68, for a total transaction of $315,000.00. Following the completion of the transaction, the chief technology officer now owns 687,473 […]

Switzerland
United-states
Swiss
Joshua-buettner-garrett
Jacobs-levy-equity-management-inc
Needham-company
Swiss-national-bank
Vanguard-group-inc
Solid-power-inc
Investment-advisers
Quadrature-capital-ltd
Nasdaq

Chardan Capital Reiterates Buy Rating for SAB Biotherapeutics (NASDAQ:SABS)

Chardan Capital reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report released on Tuesday, Benzinga reports. Chardan Capital currently has a $25.00 price target on the stock. Separately, HC Wainwright reaffirmed a buy rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a […]

Pathstone-family-office
Biotherapeutics-inc
Chardan-capital
Free-report
Family-office
Get-free-report

Dyne Therapeutics (NASDAQ:DYN) PT Raised to $42.00 at Chardan Capital

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Chardan Capital from $31.00 to $42.00 in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued reports about the company. Stifel Nicolaus increased their price […]

United-states
Jasonp-rhodes
Piper-sandler
Stifel-nicolaus
Zurcher-kantonalbank-zurich-cantonalbank
Jefferies-financial-group
Securities-exchange-commission
Raymond-james-associates
Dyne-therapeutics-company-profile
Dyne-therapeutics-inc
York-mellon-corp
Td-asset-management-inc

SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2024 earnings at ($1.02) EPS, Q3 2024 earnings at ($1.09) EPS, […]

Biotherapeutics-inc
Pathstone-family-office
Free-report
Chardan-capital
Family-office
Get-free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.